Literature DB >> 30140579

Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1.

Jennifer L Griffith1, Stephanie M Morris1, Jasia Mahdi1, Manu S Goyal1, Tamara Hershey1, David H Gutmann1.   

Abstract

BACKGROUND: We sought to define the radiologic features that differentiate neoplastic from non-neoplastic T2 hyperintensities (T2Hs) in neurofibromatosis type 1 (NF1) and identify those lesions most likely to require oncologic surveillance.
METHODS: We conducted a single-center retrospective review of all available brain MRIs from 68 children with NF1 (n = 190) and 46 healthy pediatric controls (n = 104). All T2Hs identified on MRI were characterized based on location, border, shape, degree of T1 hypointensity, and presence of mass effect or contrast enhancement, and subsequently classified using newly established radiologic criteria as either unidentified bright objects (UBOs) or probable tumors. Lesion classification was pathologically confirmed in 10 NF1 cases.
RESULTS: T2Hs were a highly sensitive (94.4%; 95% confidence interval [CI] 86.4%-98.5%) and specific (100.0%; 95% CI 92.3%-100.0%) marker for the diagnosis of NF1. UBOs constituted the majority of T2Hs (82%) and were most frequently located in cerebellar white matter, medial temporal lobe, and thalamus, where they were more likely than probable tumors to be bilateral (p < 0.001) and have nondiscrete borders (p < 0.001). Surprisingly, 57% of children with T2Hs harbored lesions classified as probable tumors, and 28% of children with probable tumors received treatment. In contrast to UBOs, probable tumors were most frequently located within the globus pallidus and medulla, and rarely occurred prior to 3 years of age.
CONCLUSIONS: With the implementation of standardized radiologic criteria, a high prevalence of brain tumors was identified in this at-risk population of children, of which nearly one-third required treatment, emphasizing the need for appropriate oncologic surveillance for patients with NF1 harboring nonoptic pathway brain tumors.

Entities:  

Year:  2018        PMID: 30140579      PMCID: PMC6105062          DOI: 10.1212/CPJ.0000000000000494

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  32 in total

1.  Development of MRI T2 hyperintensities and cognitive functioning in patients with neurofibromatosis type 1.

Authors:  Reinhold Feldmann; Gerhard Schuierer; Astrid Wessel; Nina Neveling; Josef Weglage
Journal:  Acta Paediatr       Date:  2010-11       Impact factor: 2.299

Review 2.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Authors:  D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

Review 3.  Toxic and acquired metabolic encephalopathies: MRI appearance.

Authors:  Pranshu Sharma; Muneer Eesa; James N Scott
Journal:  AJR Am J Roentgenol       Date:  2009-09       Impact factor: 3.959

4.  MRI in neurofibromatosis type I: using fluid-attenuated inversion recovery pulse sequences.

Authors:  H Yamanouchi; T Kato; H Matsuda; S Takashima; N Sakuragawa; M Arima
Journal:  Pediatr Neurol       Date:  1995-05       Impact factor: 3.372

Review 5.  Autoimmune Encephalitis: Pathophysiology and Imaging Review of an Overlooked Diagnosis.

Authors:  B P Kelley; S C Patel; H L Marin; J J Corrigan; P D Mitsias; B Griffith
Journal:  AJNR Am J Neuroradiol       Date:  2017-02-09       Impact factor: 3.825

6.  T2-weighted hyperintensities (unidentified bright objects) in children with neurofibromatosis 1: their impact on cognitive function.

Authors:  Winnie H S Goh; Pek-Lan Khong; Connie S Y Leung; Virginia C N Wong
Journal:  J Child Neurol       Date:  2004-11       Impact factor: 1.987

7.  A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1.

Authors:  Jasia Mahdi; Amish C Shah; Aimee Sato; Stephanie M Morris; Robert C McKinstry; Robert Listernick; Roger J Packer; Michael J Fisher; David H Gutmann
Journal:  Neurology       Date:  2017-03-22       Impact factor: 9.910

Review 8.  Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence.

Authors:  Annukka Lehtonen; Emma Howie; Dorothy Trump; Susan M Huson
Journal:  Dev Med Child Neurol       Date:  2012-08-31       Impact factor: 5.449

9.  Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain.

Authors:  D P DiPaolo; R A Zimmerman; L B Rorke; E H Zackai; L T Bilaniuk; A T Yachnis
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

10.  Non-optic glioma in adults and children with neurofibromatosis 1.

Authors:  Laura Sellmer; Said Farschtschi; Marco Marangoni; Manraj K S Heran; Patricia Birch; Ralph Wenzel; Jan M Friedman; Victor-Felix Mautner
Journal:  Orphanet J Rare Dis       Date:  2017-02-15       Impact factor: 4.123

View more
  5 in total

1.  MRI-guided laser interstitial thermal therapy for deep-seated gliomas in children with neurofibromatosis type 1: report of two cases.

Authors:  Kevin A Cross; Afshin Salehi; Mohamed S Abdelbaki; David H Gutmann; David D Limbrick
Journal:  Childs Nerv Syst       Date:  2022-09-15       Impact factor: 1.532

2.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Authors:  Christina Bergqvist; Amandine Servy; Laurence Valeyrie-Allanore; Salah Ferkal; Patrick Combemale; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

3.  Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1.

Authors:  Stephanie M Morris; Aditi Gupta; Seunghwan Kim; Randi E Foraker; David H Gutmann; Philip R O Payne
Journal:  Neurol Clin Pract       Date:  2021-12

4.  Nonoptic pathway tumors in children with neurofibromatosis type 1.

Authors:  Jasia Mahdi; Manu S Goyal; Jennifer Griffith; Stephanie M Morris; David H Gutmann
Journal:  Neurology       Date:  2020-04-16       Impact factor: 9.910

5.  Clinical characterization of children and adolescents with NF1 microdeletions.

Authors:  Hildegard Kehrer-Sawatzki; Lan Kluwe; Johannes Salamon; Lennart Well; Said Farschtschi; Thorsten Rosenbaum; Victor-Felix Mautner
Journal:  Childs Nerv Syst       Date:  2020-06-12       Impact factor: 1.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.